ICPT earnings call for the period ending December 31, 2019.
News & Analysis: Intercept Pharmaceuticals
Despite only having one product on the market, Intercept Pharmaceuticals is worth considering.
What does the future hold for these two biotech stocks?
Intercept's chances of remaining independent over the long-term are slim.
Amarin and Intercept Pharmaceuticals could trounce the broader markets this year.
Solid interim results from an ongoing study gave investors something to cheer about.
Big gains could be just a click of the buy button away.
Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?
ICPT earnings call for the period ending September 30, 2019.
Which of these NASH-oriented biotechs is the better buy?